Category

News Brief

AGTC Reports 12-Month Data From Its Ongoing Phase 1/2 Achromatopsia Clinical Trials Showing Biologic Activity in Patients With Mutations in the ACHM

UF startup and UF Innovate | Sid Martin Biotech alum Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, reported 12-month data from its ongoing achromatopsia (ACHM) Phase 1/2 clinical trials, including data from all adult patients and low-dose pediatric patients.

The V Foundation Announces Renewed Research Support for UF’s Dr. Duane Mitchell

During the 16th annual Dick Vitale Gala, the V Foundation for Cancer Research announced that Duane Mitchell, M.D., Ph.D., director of the UF Clinical and Translational Science Institute, assistant vice president for research at UF and co-leader of the UF Health Cancer Center’s Cancer Therapeutics & Host Response research program, will receive additional support for his research on brain cancer in children.

Atsena Therapeutics Receives Orphan Drug Designation From the FDA for Novel Gene Therapy To Treat Genetic Eye Disease LCA1

UF startup Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for its investigational gene therapy product for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1), a genetic eye disease that affects the retina.

UF Researchers Aim to One Day Farm on Mars

UF researchers are playing a part in the future of space agriculture. One of the co-directors of the UF Space Plants Lab said all the research they do has one main goal, to one day grow plants on Mars.